People with type 2 diabetes who engage in just two workouts a week are 33% less likely to die from heart complications, a new study has revealed. A team of researchers has found that exercising only ...

Elston’s Bruce Williams discuss ResMed's results and margin momentum, and whether the stock still deserves a buy rating.

As discussed in this LipoVive review, the formula is a natural weight loss aid made with clinically approved herbs and plant compounds. The main target of the formula is to support quick and ...

When I wrote about intermittent fasting in The Fast Diet with the late Michael Mosley in 2012, we often stated, sagely and with good reason, that weight-loss took effort, ...

GLP-1 medications like semaglutide and tirzepatide are helping people shed weight and keep it off. But let’s be clear: These aren’t miracle pills you buy off ...

The trial enrolled more than 13,000 participants across 30 countries and lasted more than four and a half years. It was also the largest and longest study of tirzepatide --- the active ingredient in ...

Strong Q1 sales of $137.3M showcase Madrigal Pharmaceuticals, Inc.'s Rezdiffra's growth in non-cirrhotic NASH. Click for my ...

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

As rates of childhood obesity rise, clinicians call for increased data collection to support insurance coverage and safe use of glucagon-like peptide 1 (GLP-1) medications in children under 12 years.

Weight loss drug giant Eli Lilly and Company (NYSE:LLY)’s shares have struggled in 2025 as they have lost 2.3% year-to-date.

Resmed beat Wall Street estimates for fourth-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea.